Stijn Lenders

Mr. Stijn Lenders

Medicinal chemistry, KU Leuven, Leuven, Belgium
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
FBFabio Begnini
Fabio Begnini
SGStefan Geschwindner
Stefan Geschwindner
PJPatrik Johansson
Patrik Johansson
LWLisa Wissler
Lisa Wissler
RLRichard J. Lewis
Richard J. Lewis
JKJan Kihlberg
Jan Kihlberg
Upregulation of the transcription factor Nrf2 by inhibition of the interaction with its negative regulator Keap1 constitutes an opportunity for the treatment of disease caused by oxidative stress. We report a structurally unique series of nanomolar Keap1 inhibitors obtained from a natural product-derived macrocyclic lead. Initial exploration of the structure-activity relationship of the lead, followed by structure-guided optimization, resulted in a 100-fold improvement in inhibitory potency. The macrocyclic core of the nanomolar inhibitors positions three pharmacophore units for productive interactions with key residues of Keap1, including R415, R483, and Y572. Ligand optimization resulted in the displacement of a coordinated water molecule from the Keap1 binding site and a significantly altered thermodynamic profile. In addition, minor reorganizations of R415 and R483 were accompanied by major differences in affinity between ligands. This study therefore indicates the importance of accounting both for the hydration and flexibility of the Keap1 binding site when designing high-affinity ligands.

10 August 2020 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JKJan Pascal Kahler
Jan Pascal Kahler
SLStijn Lenders
Stijn Lenders
MPMerel A. T. van de Plassche
Merel A. T. van de Plassche
SVSteven Verhelst
Steven Verhelst

Verified
Journal Article
Open access
PDF file
Luping PangLuping Pang
Luping Pang
SLStijn Lenders
Stijn Lenders
EOEvgenii M. Osipov
Evgenii M. Osipov
SWStephen Weeks
Stephen Weeks
JRJef Rozenski
Jef Rozenski
AAArthur Van Aerschot
Arthur Van Aerschot
Mycothiol (MSH), the major cellular thiol in Mycobacterium tuberculosis (Mtb), plays an essential role in the resistance of Mtb to various antibiotics and oxidative stresses. MshC catalyzes the ATP-dependent ligation of 1-O-(2-amino-2-deoxy-α-d-glucopyranosyl)-d-myo-inositol (GlcN-Ins) with l-cysteine (l-Cys) to form l-Cys-GlcN-Ins, the penultimate step in MSH biosynthesis. The inhibition of MshC is lethal to Mtb. In the present study, five new cysteinyl-sulfonamides were synthesized, and their binding affinity with MshC was evaluated using a thermal shift assay. Two of them bind the target with EC50 values of 219 and 231 µM. Crystal structures of full-length MshC in complex with these two compounds showed that they were bound in the catalytic site of MshC, inducing dramatic conformational changes of the catalytic site compared to the apo form. In particular, the observed closure of the KMSKS loop was not detected in the published cysteinyl-sulfamoyl adenosine-bound structure, the latter likely due to trypsin treatment. Despite the confirmed binding to MshC, the compounds did not suppress Mtb culture growth, which might be explained by the lack of adequate cellular uptake. Taken together, these novel cysteinyl-sulfonamide MshC inhibitors and newly reported full-length apo and ligand-bound MshC structures provide a promising starting point for the further development of novel anti-tubercular drugs targeting MshC.

26 January 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
FBFabio Begnini
Fabio Begnini
SGStefan Geschwindner
Stefan Geschwindner
PJPatrik Johansson
Patrik Johansson
LWLisa Wissler
Lisa Wissler
RLRichard J. Lewis
Richard J. Lewis
JKJan Kihlberg
Jan Kihlberg